BenevolentAI Investor Conference Presentation Deck
BEN-2293
Atopic Dermatitis (AD)
● Atopic dermatitis is the most common chronic
inflammatory skin disease, characterized by
intensely itchy, red, and swollen skin(¹)
o Affects 10-20% of children and up to 3% of
adults (2)
o Approximately 60-70% of all cases present
with mild-moderate disease severity(3)
o Prevalence is rising (3), with market value in
7MM forecast to exceed $14 billion (2,4)
• Skin inflammation and chronic pruritus
associated with atopic dermatitis negatively
impact quality of life and psychosocial
well-being(¹)
• Clear unmet need in mild to moderate patient
segment for treatment addressing itch and
inflammation, without side effects of steroids
Topical best-in-class PanTrk inhibitor to
relieve inflammation and rapidly resolve
itch in patients with AD
• BEN-2293 is a PanTrk inhibitor targeting TrkA,B
and C receptors. The Trk receptors were identified
as part of an effort to find mediators of both itch
and inflammation in AD. Using our Molecular
Design expertise we were able to design a Pan Trk
inhibitor, equipotent against the 3 receptors
BEN-2293 is expected to treat atopic dermatitis
by: inhibiting itch signaling and blocking nerve
sensitization (TrkA) in addition to inhibiting Thl
and Th2-mediated dermal inflammation (TrkB,
TrkC)
• BEN-2293 will target Mild, Moderate and Severe
Atopic Dermatitis patients, addressing unmet
need in the treatment of mild to moderate Atopic
Dermatitis as a steroid sparing alternative and in
more severe patients undergoing treatment with
systemics (e.g. dupilumab) that require add-on
treatment
Sources: (1) Weidinger et al. Nat Rev Dis Primers 2018; (2) GlobalData Report 2018: Atopic Dermatitis: Global Drug Forecast and
Market Analysis to 2027; (3) GlobalData Report 2018: Atopic Dermatitis: Epidemiology Forecast to 2027; (4) Evaluate Pharma
Benevolent 19View entire presentation